1. Scrip
  2. >>Focus On Asia
  3. >>China

Exclusive: China Likely To Implement Unique Device Identifier System By Year End

 
• By Jialing Dai

China has been talking about implementing a UDI system to track distribution of medical devices for years. PharmAsia News has learned through former CFDA and FDA experts that China is expected to implement such a system by year end.

SHANGHAI – A new regulation on Unique Device Identification is likely to come out in 2014, which could impact the local medical device industry as well as foreign companies that want to export their products to China, experts told PharmAsia News.

U.S. FDA released its much-anticipated UDI final rule in September 2013, which requires device companies to ensure all Class III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Hengrui’s Lucrative Dealmaking Year Continues With Braveheart

 
• By Joseph Haas

Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.

Chinese Drug Makers Progress HER2 ADCs Amid Enhertu Dominance

 
• By Dexter Jie Yan

A total of seven Chinese fast-followers of Enhertu are chasing the global blockbuster for a share of China’s market for HER2-targeting antibody-drug conjugates.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Chinese Biotechs Bet On FDA-Cleared Phase III Trials With First-Mover Potential

 
• By Dexter Jie Yan

Ascentage and Biokin are the latest novel drug players from China to progress potential first-in-class molecules into Phase III trials in the US. Meanwhile, Zai Lab is seeking US accelerated approval for its lung cancer candidate.

More from Focus On Asia

Mitsubishi Tanabe Names New CEO In C-Suite Reshuffle

 
• By Lisa Takagi

Under new owner Bain Capital, the Japanese firm is aiming to regain its global presence, helped by new top executives formerly with Pfizer Japan and Takeda.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.